B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice

Zhang,Cun; Wang,Weihua; Qin,Xin; Xu,Yujin; Huang,Tonglie; Hao,Qiang; Li,Weina; Wu,Shouzhen; Zhang,Yingqi

doi:10.3892/or.2013.2686

B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice

Authors:
- Cun Zhang
- Weihua Wang
- Xin Qin
- Yujin Xu
- Tonglie Huang
- Qiang Hao
- Weina Li
- Shouzhen Wu
- Yingqi Zhang
View Affiliations

Affiliations: State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: August 22, 2013 https://doi.org/10.3892/or.2013.2686
Pages: 2442-2448

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

B7-H1 is a co-inhibitory molecule belonging to the B7 family. The B7-H1 protein is only expressed on macrophage lineage of cells in normal tissues, but is overexpressed in most types of tumor. The aberrant expression of cell surface B7-H1 on cancer cells is generally associated with high-risk prognostic factors. The tumor-associated B7-H1 increases apoptosis of antigen-specific T cells through interaction with its receptor PD-1 on CD8+ T cells and contributes to tumor immune evasion. These features suggest that B7-H1 may be a therapeutic target for the B7-H1-expressing tumors. We developed a therapeutic vaccine by coupling a tetanus toxoid T-helper cell epitope with the N-terminal of B7-H1 IgV-like domain. This vaccine was able to induce high titers of antibodies against B7-H1 in mice which were able to bind to native cell surface B7-H1. We chose the B7-H1-expressing SP2/0 myeloma and its syngeneic host (the BALB/c mouse) as the model to study the antitumor activity of the rhB7-H1M vaccine. Vaccination with this modified B7-H1 protein resulted in almost complete protection from SP2/0 tumor challenge and efficiently eliminated pre-established tumors in mice. In addition, B7-H1 vaccination was able to decrease the percentage of CD4+ Foxp3+ regulatory T cells in tumor-bearing mice and which might improve antitumor immunity. These data demonstrate the potential of B7-H1-based vaccine as a therapeutic agent for the treatment of cancer overexpressing B7-H1.

View Figures

View References

1	Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999. View Article : Google Scholar : PubMed/NCBI
2	Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
3	Hansen JD, Du Pasquier L, Lefranc MP, Lopez V, Benmansour A and Boudinot P: The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol Immunol. 46:457–472. 2009. View Article : Google Scholar : PubMed/NCBI
4	Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
5	Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
6	Wintterle S, Schreiner B, Mitsdoerffer M, et al: Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63:7462–7467. 2003.PubMed/NCBI
7	Ghebeh H, Mohammed S, Al-Omair A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8:190–198. 2006. View Article : Google Scholar
8	Hasan A, Ghebeh H, Lehe C, Ahmad R and Dermime S: Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets. 15:1211–1225. 2011. View Article : Google Scholar : PubMed/NCBI
9	Thompson RH, Kuntz SM, Leibovich BC, et al: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66:3381–3385. 2006. View Article : Google Scholar : PubMed/NCBI
10	Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
11	Wilcox RA, Feldman AL, Wada DA, et al: B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114:2149–2158. 2009. View Article : Google Scholar : PubMed/NCBI
12	Selenko-Gebauer N, Majdic O, Szekeres A, et al: B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol. 170:3637–3644. 2003. View Article : Google Scholar : PubMed/NCBI
13	Fukaya T, Takagi H, Sato Y, et al: Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4⁺Foxp3⁺ regulatory T cells in the establishment of oral tolerance. Blood. 116:2266–2276. 2010. View Article : Google Scholar : PubMed/NCBI
14	Luo X, Tarbell KV, Yang H, et al: Dendritic cells with TGF-beta1 differentiate naive CD4⁺CD25⁻ T cells into islet-protective Foxp3⁺ regulatory T cells. Proc Natl Acad Sci USA. 104:2821–2826. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yamazaki S, Bonito AJ, Spisek R, Dhodapkar M, Inaba K and Steinman RM: Dendritic cells are specialized accessory cells along with TGF⁻ for the differentiation of Foxp3⁺ CD4⁺ regulatory T cells from peripheral Foxp3 precursors. Blood. 110:4293–4302. 2007. View Article : Google Scholar : PubMed/NCBI
16	Zhang C, Wu S, Xue X, et al: Antitumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. Cytotherapy. 10:711–719. 2008. View Article : Google Scholar : PubMed/NCBI
17	Dalum I, Jensen MR, Hindersson P, Elsner HI and Mouritsen S: Breaking of B cell tolerance toward a highly conserved self protein. J Immunol. 157:4796–4804. 1996.PubMed/NCBI
18	Dalum I, Butler DM, Jensen MR, et al: Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol. 17:666–669. 1999. View Article : Google Scholar : PubMed/NCBI
19	Xue X, Feng G, Li M, et al: Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine. Vaccine. 26:2873–2881. 2008. View Article : Google Scholar : PubMed/NCBI
20	Renard V, Sonderbye L, Ebbehoj K, et al: HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol. 171:1588–1595. 2003. View Article : Google Scholar
21	Valmori D, Pessi A, Bianchi E and Corradin G: Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol. 149:717–721. 1992.PubMed/NCBI
22	Yu Z, Healy F, Valmori D, Escobar P, Corradin G and Mach JP: Peptide-antibody conjugates for tumour therapy: a MHC-class-II-restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells. Int J Cancer. 56:244–248. 1994. View Article : Google Scholar
23	Suh WK, Wang S, Duncan GS, et al: Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol Cell Biol. 26:6403–6411. 2006. View Article : Google Scholar : PubMed/NCBI
24	Gallina G, Dolcetti L, Serafini P, et al: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells. J Clin Invest. 116:2777–2790. 2006. View Article : Google Scholar : PubMed/NCBI
25	Zang X and Allison JP: The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13:5271–5279. 2007. View Article : Google Scholar : PubMed/NCBI
26	Blank C, Kuball J, Voelkl S, et al: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 119:317–327. 2006. View Article : Google Scholar : PubMed/NCBI